Here's What to Expect From Viatris' Next Earnings Report Viatris is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a profit dip. Barchart · Jan 24, 2025
Viatris Stock: Is VTRS Outperforming the Healthcare Sector? Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects. Barchart · Dec 26, 2024
More ‘discreet’ Viagra-type drug could soon be available in Britain US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth The Guardian - UK · Dec 16, 2024
2 Generic Drug Stocks Ready to Surge in 2025 Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. MarketBeat · Nov 27, 2024
Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink? Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects. Barchart · Nov 6, 2024
Earnings Preview: What to Expect From Viatris' Report Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings. Barchart · Oct 27, 2024
How To Spot Good Value Stocks In A Sea Of Noise Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments. Barchart · Oct 14, 2024
Is Viatris Stock Underperforming the Dow? Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects. Barchart · Sep 23, 2024
Is Wall Street Bullish or Bearish on Viatris' Stock? Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects. Barchart · Aug 5, 2024
Viatris Quarterly Earnings Preview: What You Need to Know Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip. Barchart · Jul 26, 2024
Stocks Close Higher on Fed Rate Cut Optimism The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.85%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.16%. US stock indexes on Thursday settled higher, with the S&P 500 climbing to a... Barchart · May 9, 2024
Stocks Rise on Fed Rate Cut Hopes The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.13%. US stock indexes this morning are moderately higher, with the S&P 500 climbing... Barchart · May 9, 2024
Stocks Mixed as Weekly Jobless Claims Climb to an 8-1/2 Month High The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.27%. US stock indexes this morning are mixed, with the Dow Jones Industrials posing... Barchart · May 9, 2024
3 Pharma Stocks Outperforming the Competition The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on. StockNews.com · Mar 20, 2024
The Independent UK · Aug 8, 2023 Stock market today: Asia mixed after Wall St rallies ahead of US inflation update Asian stocks are mixed after Wall Street rallied and Japanese wages rose ahead of a U.S. inflation update that might influence Federal Reserve plans for possible interest rate hikes
Birmingham Post · Apr 27, 2023 Shield Therapeutics hails US market progress and mulls stateside listing The Gateshead company said additional losses were to be expected as it carries out a plan to target US iron deficiency treatment demand
Birmingham Post · Feb 9, 2023 Shield Therapeutics revenues boosted by US sales of iron deficiency pills The pharmaceuticals firm recently joined forced with Pennsylvania-based Viatris to tackle the American market
Birmingham Post · Dec 13, 2022 Shield Therapeutics secures £15.1m in raise and seals deal with healthcare company The iron deficiency drug specialist will use the proceeds to mount a campaign on the US market
Benzinga · Aug 8, 2022 Viatris (VTRS) Surpasses Q2 Earnings Estimates Viatris (NASDAQ: VTRS) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.
The Independent UK · Aug 4, 2022 ‘I was really struggling to get it up’: Why younger men are turning to Viagra More men in their twenties and thirties are taking little blue pills for a variety of sexual ills, from erectile dysfunction to anxiety about their performance in the bedroom. Ben Bryant speaks to users, doctors and relationship counsellors about a very curious phenomenon
Benzinga · Aug 3, 2022 Recession Investing: 5 High Yield Dividend Stocks For A Downturn As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.
Tribune News Service · Jul 5, 2022 Median pay for executives at the largest companies surged last year. A few shareholders are crying foul While it's surely not worth dwelling over, it nonetheless merits note: The highest-paid CEOs and their top-level colleagues rake in more money in one year — typically way more — than most of us will see in a lifetime.